AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.